Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $27.2000 (-0.37%) ($26.9300 - $27.9000) on Tue. Jul. 24, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.3% (three month average) | RSI | 75 | Latest Price | $27.2000(-0.37%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | ADMS advances 3.2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(22%) ONLN(20%) IBB(19%) XOP(17%) IWM(16%) | Factors Impacting ADMS price | ADMS will decline at least -1.15% in a week (0% probabilities). VIXM(-10%) UNG(-10%) BNDX(-9%) UUP(-8%) VXX(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.15% (StdDev 2.3%) | Hourly BBV | 0 () | Intraday Trend | -1% | | | |
|
5 Day Moving Average | $27.19(0.04%) | 10 Day Moving Average | $26.94(0.97%) | 20 Day Moving Average | $26.21(3.78%) | To recent high | -16.7% | To recent low | 11.8% | Market Cap | $769m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |